Sy Pretorius is the Chief Scientific Officer at PAREXEL and has been with PAREXEL for the past twenty years in a variety of roles and countries. On a day-to-day basis, Dr. Pretorius collaborates closely with biopharmaceutical and medical device clients in designing and optimizing drug / device development strategies and plans, as well as finding, evaluating and purchasing assets. Dr. Pretorius is responsible for the overall leadership of a number of PAREXEL business units – these include our global Early Phase business (responsible for Phase I and II clinical development), Global Medical Services (therapeutic area expertize, global medical writing and pharmacovigilance operations), Quantitative Clinical Development (modeling and simulation), as well as the Genomic Medicine unit. Sy Pretorius is the Chief Scientific Officer at PAREXEL and has been with PAREXEL for the past twenty years in a variety of roles and countries. On a day-to-day basis, Dr. Pretorius collaborates closely with biopharmaceutical and medical device clients in designing and optimizing drug / device development strategies and plans, as well as finding, evaluating and purchasing assets. Dr. Pretorius is responsible for the overall leadership of a number of PAREXEL business units – these include our global Early Phase business (responsible for Phase I and II clinical development), Global Medical Services (therapeutic area expertize, global medical writing and pharmacovigilance operations), Quantitative Clinical Development (modeling and simulation), as well as the Genomic Medicine unit.

Sy Pretorius is expertise in designing and optimizing drug / device development strategies and plans, as well as finding, evaluating and purchasing assets